MedTrace Logo

Faecal Analyses in Rheumatoid Arthritis Therapy

NCT03775824 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2019-09-16

No results posted yet for this study

Summary

This study evaluates the intestinal microbiome and disease activity in patients with rheumatoid arthritis receiving immunosuppressive therapy. Patients will be analysed at two time points in reference to two predefined primary endpoints:

* Changes in intestinal microbiome
* Response to therapy

The investigators want to evaluate if successful treatment of rheumatoid arthritis coincide with specific changes in the gut flora.

Conditions

Interventions

DRUG

MTX start

Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis

DRUG

TNF start

Patient prescribed TNF-inhibitor because of active rheumatoid arthritis

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Kristofer Andréasson, MD PhD · Skane University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-01
Primary Completion
2018-11-01
Completion
2019-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03775824 on ClinicalTrials.gov